Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability of its IMPACT Phase 2b MASH Trial
According to the complaint, during the class period, defendants repeatedly touted their positive expectations of the topline results of the Company's MASH trial. On June 26, 2025, Altimmune announced the results from its IMPACT Phase 2b MASH trial of Pemvidutide in the treatment of MASH. Specifically, the Company failed to achieve statistical significance in the trial due to a higher-than-expected placebo response. On this news, the price of Altimmune's common stock fell from $7.71 per share on June 25, 2025 to $3.61 per share on June 26, 25, or more than 53% in a single day.
What Now: You may be eligible to participate in the class action against Altimmune, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their papers with the court by October 6, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here .
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Altimmune, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 10, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ('Altimmune' or the 'Company') (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune's common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Altimmune's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Altimmune, Inc. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Business Upturn
14 hours ago
- Business Upturn
Digital Brands Enters into Securities Purchase Agreement for $11.225 Million Private Placement with Select Investors
Austin, TX, Aug. 09, 2025 (GLOBE NEWSWIRE) — Digital Brands Group, Inc. (OTCQX: DBGI) ('DBG' or the 'Company'), a publicly traded company specializing in eCommerce and Fashion, today announced that it has entered into a private investment in public equity ('PIPE') financing agreement with select investors (the 'Investors') for gross proceeds of approximately $11,225,000.00, after deducting placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement dated August 8, 2025 (the 'Purchase Agreement'), the Company has agreed to sell, and the Investors have agreed to purchase, up to 14,031.25shares of its Series D Convertible Preferred Stock (the 'Series D Preferred Stock'), convertible into shares of the Company's common stock, par value $0.0001 (the 'Common Stock'), subject to beneficial ownership limitations set by the Investors, at a conversion price equal to 80% of the lowest closing price of the Common Stock for each of the five trading days immediately prior to such conversion. The aggregate cash purchase price for the Series D Preferred Stock was $11,225,000, having a stated value of $14,031,250. RBW Capital Partners LLC (a division of Dawson James Securities, Inc,) acted as the placement agent in connection with the PIPE financing. The securities being offered and sold by the Company in the PIPE financing have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or state securities laws and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the 'SEC') or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares issuable upon the conversion of the Series D Preferred Stock. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Digital Brands Group We offer a wide variety of apparel through numerous brands on a direct-to-consumer and wholesale basis. We have created a business model derived from our founding as a digitally native-first vertical brand. We focus on owning the customer's 'closet share' by leveraging their data and purchase history to create personalized targeted content and looks for that specific customer cohort. Digital Brands Group, Inc. Company Contact Hil Davis, CEO Email: [email protected] Caution Regarding Forward-Looking Statements Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'is/are likely to,' 'potential,' 'continue' or other similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Insider
a day ago
- Business Insider
Shineco Inc trading halted, news pending
19:50 EDT Shineco (SISI) Inc trading halted, news pending Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
